Skip to content
NCI-H820
Tissue
轉移性
Disease
肺乳頭狀腺癌
Metastatic site
淋巴結
Synonyms
H820, H-820, NCIH820

Documents

NCI-H820

Cell line · Product number 305841

NCI-H820 is a human non-small cell lung cancer (NSCLC) cell line derived from a lung adenocarcinoma of an adult patient. It is part of the NCI lung cancer...

US$550.00excl. tax and shipping
In stock
Lot
Recommended (freshest lot)
  • CoA
1

01General information

Description

NCI-H820 是一種源自成人患者肺腺癌的人類非小細胞肺癌(NSCLC)細胞系。該細胞系隸屬於 NCI 肺癌細胞庫,因其獨特的遺傳特徵,已被廣泛應用於標靶治療的研究中。 形態學上,這些細胞呈現上皮特徵,並以黏附單層形式生長。通常將其培養於添加 10% 胎牛血清的 RPMI-1640 培養基中,並在標準細胞培養條件(37°C、5% CO₂)下維持。

在遺傳學方面,NCI-H820 的顯著特徵在於攜帶 EGFR 第 19 外顯子缺失突變(E746-A750del),這是一種常見的活化突變,與對 EGFR 酪胺酸激酶抑制劑(TKIs)的敏感性相關。 然而,該細胞系同時也攜帶次級的 EGFR T790M 突變,這已被公認為對厄洛替尼(erlotinib)和吉非替尼(gefitinib)等第一代 TKI 產生獲得性抗藥性的機制。 這種雙重突變狀態使 NCI-H820 成為研究耐藥機制以及評估第三代 EGFR 抑制劑(如奧西美替尼)的極具參考價值的模型,後者可克服由 T790M 介導的耐藥性。

除了 EGFR 突變外,NCI-H820 亦被用於研究自分泌訊號迴路及生長因子受體途徑。研究顯示,該細胞系表達 I 型胰島素樣生長因子受體(IGF-1R),有助於生存與增殖訊號傳導。 其雙重突變特徵及受體酪胺酸激酶的表達,使其成為針對 EGFR 突變型非小細胞肺癌(NSCLC)的藥物抗性、聯合治療策略及個人化治療方案開發等臨床前研究中極具價值的工具。

Tissue
轉移性
Disease
肺乳頭狀腺癌
Metastatic site
淋巴結
Synonyms
  • H820
  • H-820
  • NCIH820

02Classification

Organism
Human
Sex
Male
Growth properties
Adherent
Biosafety level
1

03Characteristics

Morphology
上皮性
Cell type
類上皮性
Tumourigenic
是的; 在裸鼠身上
Karyotype
近三倍體;模數 = 69;範圍 = 46 至 74
Doubling time
65

04Identifiers

Citation
NCI-H820(Cytion 型號 305841)
NCBI TaxID
9606
Cellosaurus
CVCL_1592

05Expression and susceptibility

Isoenzymes
AK-1,1 ES-D,1 G6PD,B GLO-I,2 Me-2,2 PGM1,1 PGM3,1
Mutational profile
突變:TP53,簡單型,p.Thr284Pro (c.850A>C),純合子

06Handling and culture

Culture medium
RPMI 1640,含 2.0 mM 穩定谷氨醯胺,含 2.0 g/L NaHCO₃(Cytion 產品編號 820700a)
Incubation atmosphere

37°C,5% CO₂,加濕環境。

Supplements
在培養基中加入 5% 的胎牛血清(FBS)
Dissociation reagent
Accutase
Fluid renewal
每週 2 至 3 次
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

  7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

  8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

07Quality control and cryopreservation

Sterility

透過基於 PCR 的檢測及基於發光原理的支原體檢測方法,排除支原體污染的可能性。

為確保無細菌、真菌或酵母菌污染,每日均會對細胞培養物進行目視檢查。

Freeze medium
作為冷凍保存培養基,我們使用完全生長培養基(含 FBS)+ 10% DMSO 以確保解凍後的存活率,或使用 CM-1 (Cytion 型號 800100),該培養基含有經優化的滲透保護劑和代謝穩定劑,可提升細胞恢復率並減輕冷凍誘導的壓力。
Storage conditions

若需長期保存,請將試管置於溫度約為 −150 至 −196 °C 的氣相液氮中。僅在轉移至液氮之前,可將試管暫時存放於 −80 °C 環境中,作為短期過渡步驟。

Shipping conditions

冷凍保存的細胞系會以乾冰冷藏,並裝於經驗證的隔熱包裝中,包裝內含有足夠的冷媒,以確保在運輸過程中溫度維持在約 −78 °C。收到貨物後,請立即檢查容器,並盡快將試管轉移至適當的儲存場所。

08Donor

Donor age
53年
Ethnicity
高加索人